OncoGenex to Report Financial Results for Fourth Quarter and Year-Ended 2013
on March 11, 2014
BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 25, 2014 /CNW/ -
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the
Company's fourth quarter and year-ended 2013 financial results will be
released on Tuesday, March 11, 2014, and that the Company will host a
conference call and live webcast at 4:30 p.m. ET that afternoon. Management
will provide an overview of the company's financial results, development
programs and a general business update.
To access the webcast, log on to the Investor Relations page of the OncoGenex
website at www.oncogenex.com. Alternatively, you may access the live
conference call by dialing (877) 606-1416 (U.S. & Canada) or (707) 287-9313
(International). A webcast replay will be available approximately two hours
after the call and will be archived on www.oncogenex.com for 90 days.
ABOUT ONCOGENEX OncoGenex is a biopharmaceutical company committed to the
development and commercialization of new therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with
each product candidate having a distinct mechanism of action and representing
a unique opportunity for cancer drug development. OncoGenex and Teva
Pharmaceutical Industries Ltd. have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer and in
patients with advanced, unresectable non-small cell lung cancer. Apatorsen is
currently being evaluated in seven randomized Phase 2 trials for a variety of
cancers and OGX-225 is currently in pre-clinical development. More information
is available at www.OncoGenex.com and at the company's Twitter account:
SOURCE OncoGenex Pharmaceuticals, Inc.
Media Contact: Jaime Welch, firstname.lastname@example.org, 604-630-5403, Investor
Relations Contact: Susan Specht, email@example.com, 425-686-1535
To view this news release in HTML formatting, please use the following URL:
CO: OncoGenex Pharmaceuticals, Inc.
ST: British Columbia
NI: HEA MTC CONF
-0- Feb/25/2014 11:30 GMT
Press spacebar to pause and continue. Press esc to stop.